Potassium channel opener
A potassium channel opener comprising a compound (e.g., pimaric acid) represented by the formula [I]: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently hydrogen, alkyl, alkenyl, halogen, hydroxy, halogenated alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, heteroaryl, acyl, carboxyl, alkoxycarbonyl, hydroxamate, sulfo, carbamoyl, sulfonamide, aldehyde, or nitrile; or R 4 and R 5 may be bonded to each other to form a ring; or R 6 and R 7 may be bonded to each other to form a ring; and all of three bonds represented by are single bonds, or one of the three bonds is double bond and the other bonds are single bonds, or a physiologically acceptable salt thereof as an effective ingredient.
1. A method of treatment of hypertension, tonic bladder, disturbances of peripheral circulation, airway hyperresponsiveness, sensory neuron hypersensitivity, central spasm or ischemic central nervous system disorder, which comprises administering a compound, or a physiologically acceptable salt thereof as an active ingredient, wherein the compound is represented by the formula:
wherein R 12 is acyl, carboxyl, hydroxamate, sulfo, carbamoyl, sulfonamide or nitrile;
wherein R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 are each independently hydrogen, alkyl, alkenyl, halogen, hydroxy, halogenated alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, heteroaryl, acyl, carboxyl, carboxyl, alkoxycarbonyl, hydroxamate, sulfo, carbamoyl, sulfonamide, aldehyde or nitrile; or R 20 and R 21 may be bonded to each other to form oxo.
2. The method according to claim 1 , wherein R 11 , R 13, and R 18 are alkyls, R 12 is carboxyl, R 14 , R 15 and R 16 are hydrogen, or a physiologically acceptable salt thereof.
3. The method according to claim 1 , wherein R 11 , R 13 and R 18 are alkyls, R 12 is carboxyl, R 14 , R 15 , R 16 , R 20 , and R 21 are hydrogen, and R 17 and R 19 are halogen, or a physiologically acceptable salt thereof.
4. The method according to claim 1 , which method is for treatment of essential hypertension, tonic bladder, airway hyperresponsiveness, or ischemic central nervous system disorder.
5. The method according to claim 1 , wherein said compound is dichlorodehydroabietic acid.